Wolwo Pharma(300357)2025-04-20 10:13Financial Performance - In 2024, the company achieved a revenue of 925,394,524.96 RMB, a year-on-year increase of 9.10% [2] - The net profit attributable to shareholders was 317,822,381.76 RMB, up 43.52% compared to the previous year [2] - In Q1 2025, the revenue was 228,471,779.62 RMB, reflecting a growth of 5.65% year-on-year [2] - The net profit for Q1 2025 was 74,342,067.14 RMB, a decrease of 3.71% from the same period last year [2] Product Sales Performance - Sales revenue for "Dust Mite Drops" in 2024 was 1,215,804,998.41 RMB, an increase of 4.10% year-on-year [2] - Sales revenue for "Artemisia Flower Pollen Sublingual Drops" reached 9,300,884.66 RMB, marking a growth of 76.43% [2] - Sales revenue for "Skin Prick Test Solution" was 2,336,289.25 RMB, with a significant increase of 104.58% year-on-year [3] R&D Pipeline - As of December 2024, the company has received approval for three new skin prick test products, expanding its portfolio to a total of 8 approved products [3] - The "House Dust Mite Membrane" drug clinical trial application was approved in December 2024, entering Phase I clinical trials in March 2025 [3][6] Dividend Distribution - The company announced a cash dividend of 1.20 RMB per 10 shares, totaling approximately 62,830,080.00 RMB, subject to shareholder approval [4] - Cumulatively, the company has distributed over 850 million RMB in cash dividends since its listing, equivalent to about four times the initial fundraising amount [3] Sales Strategy and Market Position - The company is enhancing its sales management structure and has selected a group of young sales managers to take on more responsibilities [6] - The positioning of the "House Dust Mite Membrane" product focuses on sublingual administration, improving patient compliance and accuracy [7] Conclusion - The company aims to maintain its leading position in the desensitization field while optimizing internal processes and enhancing operational efficiency [8]